BiotechTube

capecitabine + lapatinib + trastuzumab

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastases, Brain

Conditions

Metastases, Brain

Trial Timeline

Apr 14, 2009 → Mar 22, 2018

NCT ID
NCT00820222

About capecitabine + lapatinib + trastuzumab

capecitabine + lapatinib + trastuzumab is a phase 3 stage product being developed by Novartis for Metastases, Brain. The current trial status is completed. This product is registered under clinical trial identifier NCT00820222. Target conditions include Metastases, Brain.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00820222Phase 3Completed

Competing Products

20 competing products in Metastases, Brain

See all competitors
ProductCompanyStageHype Score
LY2780301Eli LillyPhase 1
33
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Patritumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
77
Leuprorelin AcetateAstellas PharmaPhase 3
77
Pembrolizumab + LenvatinibEisaiPhase 2
52
ALIMTA + folic acid + multi-vitaminsEli LillyPhase 1
33
MerestinibEli LillyPhase 1
33
LY2584702 + Erlotinib + EverolimusEli LillyPhase 1
33
Veliparib + PlaceboAbbViePhase 2
52
temozolomideMerckPhase 2
52
VorinostatMerckPhase 1
33
PembrolizumabMerckPhase 2
52
EMD 525797MerckPhase 1
33
TemozolomideMerckPhase 2
52
cabazitaxel + lapatinibNovartisPhase 2
52
BKM120 + capecitabine + TrastuzumabNovartisPhase 2
52
Zoledronic acidNovartisPhase 3
77
zoledronic acidNovartisPhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85